

## Claims

- Sub 5
1. A combination comprising paracetamol or a non-steroidal anti-inflammatory drug (NSAID), or a pharmaceutically acceptable salt or solvate thereof, and another drug, characterised in that the other drug is mirtazapine, or a pharmaceutically acceptable salt or solvate thereof, optionally in association with one or more pharmaceutically acceptable carriers.
  - 10 2. The combination according to claim 1, characterised in that the combination comprises a pharmaceutical composition which comprises both mirtazapine and paracetamol or an NSAID, optionally in association with one or more pharmaceutically acceptable carriers.
  - 15 3. The combination according to claim 1 or 2, characterised in that the combination is with the NSAID ibuprofen.
  4. Use of mirtazapine in combination with paracetamol or an NSAID in the manufacture of a medicament for the treatment of headache.
  - 20 5. Use of mirtazapine in the manufacture of a medicament, characterised in that the medicament is for the treatment of headache, which treatment comprises administration of mirtazapine in combination with paracetamol or an NSAID
  - 25 6. The use of mirtazapine for the manufacture of a medicament, characterised in that the medicament is for the treatment of headache comprising the administration of mirtazapine with a unit treatment dose comprising between 0.1 and 5 mg mirtazapine.
  - 30 7. Use of paracetamol or an NSAID in the manufacture of a medicament for the treatment of headache, characterised in that the medicament is for administration in combination with mirtazapine.
  - 35 8. The uses according to any one of claim 4 to 8, characterised in that the headache is tension-type headache.

Sub  
A2  
5  
9. A method for the treatment of headache in a subject which method comprises treating said subject with an effective amount of mirtazapine in combination with paracetamol or an NSAID.

10. A method of treatment of headache in a subject comprising the administration of an amount of mirtazapine, characterised in that the amount is between 0.1 and 5 mg mirtazapine.

10 11. The method of treatment according to claim 3, characterised in that the headache is tension-type headache.

15 12. A patient pack for the treatment of headache comprising means for administration of metered dose units in combination with packaging material suitable for said dose units, characterised in that the patient pack comprises mirtazapine and comprises paracetamol or an NSAID and optionally, said packaging material is including means to help a recipient using the dose units most suitably for the treatment headache.

20 13. A patient pack for the treatment of headache comprising means for administration of metered dose units in combination with packaging material suitable for said dose units, characterised in that the dose units comprise pharmaceutical auxiliaries and mirtazapine in an amount between 0.1 and 5 mg and optionally, said packaging material is including means to help a recipient using the dose units most suitably for the treatment headache.

25

AA3